MK 8591

Drug Profile

MK 8591

Alternative Names: 4-ethynyl-2-fluoro-2-deoxyadenosine; EFdA; MK-8591

Latest Information Update: 18 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiretrovirals
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV-1 infections
  • Preclinical HIV-2 infections

Most Recent Events

  • 11 May 2017 Merck Sharp & Dohme completes the phase I MK-8591-003 trial for HIV-1 infections (Monotherapy, Treatment -naive) in Germany (PO) (NCT02217904)
  • 17 Apr 2017 Chemical structure information added
  • 13 Feb 2017 Preclinical trials in HIV-2 infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top